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Abstract
Sleep restriction is associated with impaired glucose metabolism and insulin
resistance, however, the underlying mechanisms leading to this impairment are
unknown. This study aimed to assess whether the decrease in insulin sensitivity
observed after sleep restriction is accompanied by changes in skeletal muscle
PKB activity. Ten healthy young males participated in this randomized cross-
over study which included two conditions separated by a 3-week washout per-
iod. Participants underwent two nights of habitual sleep (CON) and two nights
of sleep which was restricted to 50% of habitual sleep duration (SR) in the
home environment. Whole-body glucose tolerance and insulin sensitivity were
assessed by an oral glucose tolerance test after the second night of each condi-
tion. Skeletal muscle tissue samples were obtained from the vastus lateralis to
determine PKB activity. Findings displayed no effect of trial on plasma glucose
concentrations (P = 0.222). Plasma insulin area under the curve was higher
after sleep restriction compared to the control (P = 0.013). Matsuda index was
18.6% lower in the sleep restriction (P = 0.010). Fold change in PKB activity
from baseline tended to be lower in the sleep restriction condition at 30 min
(P = 0.098) and 120 min (P = 0.087). In conclusion, we demonstrated
decreased whole-body insulin sensitivity in healthy young males following two
nights of sleep restriction. Skeletal muscle insulin signaling findings are incon-
clusive and require further study to examine any potential changes.
Introduction
Reduced sleep is associated with a number of disorders
related to health (Steptoe et al. 2006; Cappuccio et al.
2010), with the relationship between sleep restriction and
impaired metabolism being well established (Morselli
et al. 2010). Evidence shows that chronic short sleep
duration increases the risk of developing cardiovascular
diseases (Sabanayagam and Shankar 2010) as well as
metabolic disorders (Gottlieb et al. 2005). Furthermore,
acute sleep restriction studies have demonstrated impaired
glucose clearance and decreased glucose effectiveness
(Steptoe et al. 2006; Buxton et al. 2010; Donga et al.
2010; Schmid et al. 2011). Reduced glucose clearance fol-
lowing sleep restriction has been previously shown to be
due to impaired insulin sensitivity (Buxton et al. 2010;
Donga et al. 2010; Broussard et al. 2012; Rao et al. 2015;
Wang et al. 2016) which can be reduced by up to 25%
after only a single night of sleep restriction (Donga et al.
2010), or by restricting sleep by only 1–3 h for 3 consecu-
tive nights in young healthy adults (Wang et al. 2016).
Collectively, these data demonstrate that even acute mild
sleep restriction may be detrimental to both glucose regu-
lation and insulin sensitivity.
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Many studies have shown an impairment in whole-body
glucose metabolism following sleep restriction, however, less
is known about the mechanisms responsible for this impair-
ment in glucose regulation. Recent work suggests the
impairment may be the result of a defect in peripheral tis-
sues. Rao et al. (2015) assessed insulin sensitivity following
sleep restriction and demonstrated that peripheral insulin
sensitivity was decreased while hepatic insulin sensitivity was
unchanged, indicating that a defect in the peripheral tissues
may be influential in the impairment in whole-body glucose
regulation after sleep loss. Broussard et al. (2012) have
demonstrated that sleep restriction influences whole-body
insulin sensitivity which is coupled with an impairment in
insulin signaling in adipocytes. These data suggest that an
impairment in insulin signaling in adipose tissue may con-
tribute to the whole body impairment in glucose control.
However, while adipose tissue is an active component of glu-
cose regulation, it is likely that other peripheral tissues, such
as skeletal muscle may contribute to glucose control. Skeletal
muscle accounts for up to 80% of glucose clearance under
insulin-stimulated conditions (Thiebaud et al. 1982). There-
fore, it is possible that any actions of sleep restriction on
insulin signaling within skeletal muscle may contribute to
the impairments in whole-body glucose homeostasis.
Protein kinase B (PKB), also known as Akt, plays an
important role in the insulin signaling pathway which can
influence glucose uptake in skeletal muscle and adipose
tissue. PKB is activated by the insulin receptor substrate 1
(IRS1) through PtdIns 3-kinase and phosphorylation of
3-phosphoinositide-dependant kinase (PDK1). Activation
of PKB then leads to GLUT4 translocation and results in
glucose uptake (Hancock 2010). An impairment of PKB
activity can lead to disruption of the insulin signaling
pathway, thus, causing a reduced response to insulin.
To our knowledge no published studies have investigated
the effects of sleep restriction on PKB activity within skeletal
muscle, therefore, we sought to address this gap in the litera-
ture. The aims of the present study were to (1) investigate
the effects of acute sleep restriction on whole-body glucose
tolerance and insulin sensitivity and (2) investigate if any
changes in whole-body insulin sensitivity are accompanied
by changes in PKB activity in skeletal muscle following acute
sleep restriction. We hypothesized that whole-body glucose
tolerance and insulin sensitivity would decrease and PKB
activity within skeletal muscle would be impaired following
two nights of partial sleep restriction.
Methods
Study design
Ten participants were recruited by advertisement from
the university and local area to take part in this
randomized crossover trial. The study involved a pre-
screening visit followed by two main trials, which were
separated by a 3-week washout period. Inclusion criteria
included healthy males aged 18–40 years who were non-
smokers with a normal regular sleeping pattern, defined
as 7–9 h of sleep each night at approximately the same
time of day. Individuals were excluded if they had trav-
elled across time zones or carried out shift work in the
past 4 weeks, reported any sleep disorders, scored >5 after
completing the Pittsburgh Sleep Quality Index (Buysse
et al. 1989), suffered from any health conditions such as
inflammatory and metabolic disorders, or were taking
medications that would interfere with metabolism. All
volunteers were informed of the procedures and gave
written consent prior to participating in the study which
was approved by the University of Stirling, School of
Sport research ethics committee.
Prescreening visit
Participants arrived at the laboratory where height and
body mass were recorded. Participants completed a stan-
dard health questionnaire, a morningness–eveningness
questionnaire (Horne and Ostberg 1976) and the Pitts-
burgh Sleep Quality Index (PSQI) (Buysse et al. 1989) to
assess overall health and sleep characteristics prior to the
study. Each participant was advised on how to complete a
7-day sleep diary and 3-day food diary, which were to be
completed before beginning the main trial. In conjunc-
tion, participants wore a wrist watch actigraphy monitor
(GENEActiv, Activinsights Ltd., Cambridgeshire, UK)
during the 7-day period to objectively measure habitual
sleep duration prior to the first entraining period.
Entraining
Prior to each main trial, participants underwent 1 week
of entraining in their home environment. During the
entraining period participants were instructed continue
with their normal routine activities and to go to bed and
wake at the same time, daily, which was a similar time to
their habitual sleeping patterns. Wrist watch actigraphy
(GENEActiv, Activinsights Ltd., Cambridgeshire, UK) was
used throughout the entraining period to ensure compli-
ance.
Trial conditions
Following the entraining period participants were
instructed on their individual time to go to bed and wake
in their home environment. Experimental trials consisted
of two consecutive nights of either control sleep (CON),
a time calculated from the mean habitual sleep duration
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which was determined from the actigraphy monitors and
confirmed using the 7-day sleep diary, or two nights of
sleep restriction (SR), which was determined as 50% of
mean habitual sleep duration. During the sleep restriction
trial, participants slept the second half of the night to
ensure laboratory measurements were obtained at the
same time from wakening in both trials. To confirm com-
pliance during the sleep restriction trial, participants wore
wrist actigraphy monitors and sent time-stamped SMS
messages to the researcher every hour from their habitual
bed time until their sleep restricted bed time.
During the trials, participants were supplied with a 48-
h diet based on their habitual food intake from the 3-day
food diary. This diet was replicated for each trial and par-
ticipants were instructed to eat only the foods provided
during this 48 h period. Participants were asked to con-
tinue with their normal daily routines throughout the tri-
als, but to avoid any vigorous physical activity or
consumption of caffeine or alcohol. For safety reasons,
participants were collected each morning from their home
by a researcher and driven to the laboratory and returned
home following each laboratory visit. Participants were
instructed not to operate heavy machinery or perform
tasks that may risk their safety during the trial. Partici-
pants received regular phone calls from the researchers
and were instructed to have a recovery night sleep follow-
ing the two nights of sleep restriction.
Laboratory visits
Following the second night of sleep restriction or control
sleep, participants arrived at the laboratory in a rested
and fasted state. Height and body mass were measured.
Participants then rested in the supine position for 5 min
before blood pressure and heart rate were measured using
a digital blood pressure monitor (Hangzhou Sejoy Elec-
tronics & Instruments Co., LTD, China). A cannula was
inserted into the antecubital vein of the participant’s arm
to allow blood samples to be drawn at regular intervals.
An oral glucose tolerance test (OGTT) was then carried
out. Participants were given a drink solution consisting of
82.5 g of dextrose (Myprotein, Cheshire, UK) mixed with
300 ml of water, which they were instructed to consume
all at once. Blood samples were collected before (0 min)
and at 15, 30, 45, 60, 90, and 120 min following con-
sumption of the drink. Muscle tissue samples were also
obtained before (0 min) and at 30 and 120 min after the
drink was consumed.
Blood collection and processing
All blood samples during the OGTT were obtained by the
cannulation technique. Ten mL of blood was collected for
each sample into EDTA-treated and serum separator
vacutainer tubes. After collection, serum samples were
allowed to clot at room temperature for 30 min while
EDTA-treated blood samples were placed on ice, until
centrifugation. All samples were centrifuged at 1780 g at
4°C for 10 min. Plasma was aliquoted into microtubes
and stored at 70°C until analysis.
Muscle tissue collection and preparation
Participants laid in the supine position during the OGTT
while muscle biopsies were obtained from the vastus lat-
eralis using the Bergstrom biopsy technique. Biopsies were
obtained from the same limb during the OGTT with
alternate limbs used in each condition. Biopsies were
taken initially at the most proximal point, then approxi-
mately 3–5 cm distally for each biopsy. The site was
cleaned and the local area was anesthetized by injection
of 2% Lidocaine (B. Braun, Sheffield, UK). Approximately
60–100 mg of skeletal muscle tissue was obtained for each
sample. Samples were immediately cleaned with a saline
solution and placed into microtubes. The tissue was then
snap frozen using liquid nitrogen and stored at 70°C
until analysis.
Plasma glucose and insulin assays
Plasma glucose levels were measured from EDTA-treated
blood samples collected at 0, 15, 30, 45, 60, 90, and
120 min during the OGTT. Plasma glucose was assayed
in duplicate using an ILab automated analyzer (Instru-
mentation Laboratory, Warrington, Cheshire, UK). Serum
insulin was analyzed in duplicate using ELISA techniques
from a commercially available kit (Demeditec, Kiel, Ger-
many).
Kinase assay
Prior to conducting activity assays, skeletal muscle tissue
was processed as described previously (McGlory et al.
2014). Activity assays to determine panPKB activity were
then conducted as described previously (McGlory et al.
2014). Briefly, kinase assays were carried out by immuno-
precipitation for 2 h at 4°C in homogenization buffer
(50 mmol/L TrisHCl pH 7.5, 0.1 mmol/L EGTA,
1 mmol/L EDTA, 1% [vol/vol] Triton X-100, 50 mmol/L
NaF, 5 mmol/L NaPPi, 0.27 M sucrose, 0.1% b-mercap-
toethanol, 1 mmol/L Na3(OV)4, and 1 Complete [Roche]
protease inhibitor tablet per 10 mL). Activity assays for
panPKB were carried out on cell lysates by IP from
300 lg of cell lysate. The IP step was performed with
2 lg each of PKBa/b/c antibodies (DSTT, Dundee
University). Antibodies were used with 2.5 lL of protein
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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G sepharose per IP to immunoprecipitate for 2 h at 4°C.
The activity assay ran for 2 h.
Statistical analysis
Data were analyzed using Minitab v.17 statistical software
(Minitab Ltd., United Kingdom). Data for participant
characteristics and sleep time are presented as
mean  SD. Data for plasma glucose, insulin, and muscle
PKB are presented as mean  SEM. 2 9 7 (trial 9 time)
repeated measures ANOVA were used to analyze plasma
glucose and insulin. Paired t-tests were carried out post
hoc to identify any differences within main effects. Data
that violated the assumption of normality were trans-
formed prior to carrying out any statistical tests. A
P < 0.05 was used for significance. The Matsuda index
(Matsuda and DeFronzo 1999) was used to calculate insu-
lin sensitivity. Area under the curve for glucose and insu-
lin were calculated using the trapezoidal rule. Cohen’s d
effect sizes and confidence intervals were calculated for
PKB activity.
Results
Ten males completed the study. Participant characteristics
are displayed in Table 1.
Sleep characteristics
Participants’ mean habitual time to bed and wakening
time were 23:44 h and 07:42 h, respectively. Mean habit-
ual sleep duration was 484  66 min. During CON and
SR mean time to bed was 23:49 h and 03:19 h and mean
wakening time was 07:11 h and 07:14 h, respectively.
Mean sleep duration during the control and SR condition
was 442  78 min and 235  34 min, respectively. Con-
trol sleep and habitual sleep were not significantly
different (P = 0.124), however, sleep duration in the SR
condition was significantly shorter than in the control
condition (P < 0.001).
Blood plasma variables
Mean plasma glucose and insulin concentrations during
the OGTT are displayed in Figure 1. Repeated measures
ANOVA revealed a main effect of time for plasma glucose
(P < 0.001). There was no effect of trial (P = 0.222) or
trial 9 time (P = 0.985). Mean baseline plasma glucose
concentrations during CON were similar to SR
(4.92  0.1 mmol/L and 5.02  0.06 mmol/L, respec-
tively) (Fig. 1A). Similarly, AUC was not different
between conditions (P = 0.391) (Fig. 1B).
Mean plasma insulin concentrations showed main
effects of trial and time during the OGTT (P = 0.006 and
P < 0.001, respectively). Plasma insulin values were simi-
lar at baseline in CON and SR (18.7  4.9 lIU/mL and
20.0  5.0 lIU/mL, respectively; P = 0.172). SR displayed
significantly higher insulin concentrations than CON at
15 min (59.1  9.0 lIU/mL and 48.5  9.5 lIU/mL for
SR and CON, respectively; P = 0.031) and at 45 min
(83.9  10.2 lIU/mL and 67.3  10.8 lIU/mL for SR
and CON, respectively; P = 0.028) (Fig. 2A). AUC for
insulin was 14% higher in the sleep restriction condition
compared to the control (7069  1018 vs. 8068  901
for CON vs. SR, respectively; P = 0.013) (Fig. 2B). Mat-
suda index was 19% lower in SR than CON (4.19  0.71
vs. 3.41  0.51 for CON and SR, respectively; P = 0.010).
Skeletal muscle insulin signaling
PKB activity is shown in Figure 3. One participant was
excluded from the results for PKB activity due to techni-
cal issues, therefore N = 9 for all PKB activity results. A
main effect of time was demonstrated for panPKB activity
(P = 0.001) and there was a trend for trial 9 time
(P = 0.087). There was no main effect of trial
(P = 0.589). PanPKB activity during CON was
12.37  1.93 lU/(minmg) at baseline and was signifi-
cantly elevated at 30 min (26.67  4.96 lU/(minmg);
P = 0.007) and 120 min (21.47  2.75 lU/(minmg);
P < 0.001). PanPKB during SR was 27% higher than
CON at baseline which showed a medium effect size
(mean difference +3.35 lU/(minmg); 95% CI: 1.91,
8.61; d = 0.63) and showed a 16% lower response than
CON at 30 min which displayed a small effect (mean dif-
ference 4.38 lU/(minmg); 95% CI: 9.60, 0.85;
day = 0.32). PanPKB was similar between conditions at
120 min (21.47  2.75 lU/(minmg) for CON and
21.40  2.69 lU/(minmg) for SR; 95% CI: 6.38, 6.24;
d = 0.01) (Fig. 3A).
Table 1. Participant characteristics at baseline.
Age (years) 23  4
Height (cm) 181.6  5.8
Body mass (kg) 82.2  9.5
Body mass index (kg/m2) 24.9  2.1
Systolic blood pressure (mmHg) 125  5
Diastolic blood pressure (mmHg) 70  4
Habitual energy intake (kcal/day) 2369  616
PSQI score 4  1
Morningness–eveningness score 53  8
Data presented as mean  SD. N = 10. PSQI, Pittsburgh Sleep
Quality Index; PSQI score ≥5 is indicative of poor sleep quality.
Morningness–eveningness score of 16 reflective of “definite eve-
ning type” and score of 86 “definite morning type.” A score of
42–58 is indicative of “neither type.”
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PanPKB activity displayed a mean of a 2.7 fold change
from baseline to 30 min in CON whereas the 1.5 fold
change during SR tended to be lower (1.13 difference in
fold change; 95% CI: 2.91, 0.65; P = 0.098, d = 0.69).
Similarly, PKB activity showed a mean of 1.9 fold change
from baseline to 120 min during CON while the 1.4 fold
change during SR also tended to be lower (0.49 differ-
ence in fold change; 95% CI: 1.03, 0.04; P = 0.087,
d = 1.08) (Fig. 3B).
Discussion
The aim of the present study was to investigate if the
reduction in whole-body insulin sensitivity following
acute sleep restriction was accompanied by any changes
in skeletal muscle PKB activity, a protein kinase that pro-
motes GLUT4 translocation and glucose uptake via the
insulin signaling pathway. Our results demonstrate that
two nights of sleep restriction impaired whole-body insu-
lin sensitivity; our findings regarding skeletal muscle insu-
lin signaling following sleep restriction are inconclusive,
although they do point toward potential decreases in the
response of skeletal muscle PKB activity to glucose intake
in healthy young men.
Plasma glucose concentrations were not altered follow-
ing sleep restriction in our study. Baseline glucose values
were similar between SR and CON; and furthermore, the
plasma glucose response during the OGTT did not signif-
icantly differ between the conditions. This finding is in
agreement with some previous studies (Zielinski et al.
A B
Figure 1. Plasma glucose concentrations. Mean plasma glucose concentrations (A) and glucose area under the curve (AUC) (B) during the
OGTT following two nights of normal sleep (CON) or sleep restriction (SR) (N = 10). Data are expressed as mean  SEM. Repeated measures
ANOVA followed by paired t-test (where appropriate) used to analyze data.
A B
Figure 2. Plasma insulin concentrations. Mean plasma insulin concentrations (A) and insulin area under the curve (AUC) (B) during the OGTT
following two nights of normal sleep (CON) or sleep restriction (SR) (N = 10). Data are expressed as mean  SEM. Repeated measures ANOVA
followed by paired t-test (where appropriate) used to analyze data. * indicates significantly higher values in SR condition (P < 0.05).
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2008; Schmid et al. 2009; Wang et al. 2016). However,
differences have also been observed (Spiegel et al. 1999;
Nedeltcheva et al. 2009; Buxton et al. 2010; Reynolds
et al. 2012; Rao et al. 2015). We speculate that the differ-
ences between studies may be due to the severity of sleep
loss. Studies that have shown differences in the plasma
glucose response employed a more severe sleep restriction
protocol than the present study. Typically, previous stud-
ies have used a set duration of sleep as a control, and/or
compared sleep restriction to an extended period of sleep
(e.g., 10 or 12 h). A limitation to this type of protocol is
the possible individual differences in habitual sleep dura-
tion. The present study used habitual sleep duration as
the control condition to overcome these limitations and
employed a sleep restriction protocol which was relative
to habitual sleep duration to account for possible individ-
ual differences.
We demonstrated an increased plasma insulin response
during the OGTT following sleep restriction when com-
pared to the control condition, which is consistent with
previous studies (Buxton et al. 2010; Donga et al. 2010;
Broussard et al. 2012; Rao et al. 2015). A higher plasma
insulin response in the SR condition without any changes
in plasma glucose implies that the sleep restriction proto-
col in our study led to reduced whole-body insulin sensi-
tivity. This is supported by a lower Matsuda index value
following SR. Wang et al. (2016) demonstrated similar
findings to the present study, showing a lower Matsuda
index value after three nights of sleep restriction. The
mechanisms for reduced whole-body insulin sensitivity
following sleep restriction are likely to be multifactorial.
Sleep restriction has been shown to lead to insulin resis-
tance in peripheral tissues (Rao et al. 2015), including
adipose tissue (Broussard et al. 2012).
We assessed the activity of PKB in skeletal muscle at
baseline, 30 min, and 120 min during the OGTT.
Although we did not find a statistically significant differ-
ence for PKB activity between the conditions, our results
showed a propensity for a reduced change in PKB activ-
ity in response to glucose intake in the sleep restriction
condition compared to the control condition. During
CON, PKB activity increased 2.7-fold 30 min following
ingestion of the drink, whereas during SR the increase
was only 1.5-fold. Similarly, at 120 min there was an
increase of 1.9-fold in CON compared to only 1.4-fold
in SR. Changes in PKB following sleep restriction have
been previously shown in adipose tissue by Broussard
et al. (2012). Phosphorylated PKB within adipocytes was
reduced following glucose infusion in a sleep restricted
condition compared to normal sleep. To our knowledge
the present study is the first to investigate insulin signal-
ing within skeletal muscle tissue following sleep restric-
tion. The mild changes in PKB activity found in the
present study may reflect the acute nature of the study,
indicating that two nights may not be sufficient to elicit
changes of a magnitude which can be detected at the
tissue level. Furthermore, differences between studies
could be due to methodologies. Broussard et al. (2012)
assessed insulin sensitivity using frequently sampled
intravenous glucose tolerance tests (IVGTT), where as
we employed an oral glucose tolerance test (OGTT).
While the OGTT demonstrates ecological validity, skele-
tal muscle exposure to circulating insulin can vary
between participants. Therefore, it would be beneficial to
explore this finding further using the gold standard eug-
lycemic–hyperinsulinemic clamp in future studies, as
well as investigating more severe sleep restriction proto-
cols.
A
B
Figure 3. Skeletal muscle PKB activity. Skeletal muscle protein
kinase B (PKB) activity during the OGTT following two nights of
normal sleep (CON) or sleep restriction (SR) (N = 9). (A) PanPKB
activity at each time point. Data are expressed as mean  SEM. (B)
Individual PKB activity fold change from baseline at 30 and
120 min.
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The effect of chronic sleep restriction on skeletal mus-
cle insulin signaling is unknown. However, based on our
results, we speculate that repeated exposure to sleep
restriction, leading to disruption of whole-body insulin
sensitivity and propensity to a reduced response of PKB
activity, could manifest to a possible defect in the insulin
signaling pathway. Previous research suggests that a
chronic increase in circulating insulin can lead to
impaired insulin signaling within skeletal muscle, which is
thought to be the initial defect leading to insulin resis-
tance and the development of type 2 diabetes (DeFronzo
and Tripathy 2009).
The mechanisms underlying the impairment in insulin
sensitivity following sleep restriction are likely to be mul-
tifactorial, including involvement of both skeletal muscle
and adipose tissue among others. Sleep restriction is often
accompanied by increased inflammatory markers (Vgont-
zas et al. 2004; Irwin et al. 2006). Inflammation has been
shown to disrupt insulin signaling in skeletal muscle
(Plomgaard et al. 2005). Increased concentrations of the
proinflammatory cytokine TNF-a can impair glucose
uptake within skeletal muscle by targeting multiple steps
in the insulin signaling pathway including IRS-1 and
AS160 phosphorylation (Plomgaard et al. 2005). There-
fore, the possibility of inflammation as a possible media-
tor between sleep restriction and impaired insulin
signaling should be explored.
Insulin sensitivity can be influenced by sleep, physical
activity, and food intake. With this in mind, the majority
of sleep restriction studies examining insulin sensitivity
have been conducted in laboratory or in-patient settings
where these factors can be controlled. We chose to per-
form the sleep restriction protocol in the home environ-
ment. Indeed, while we attempted to control for these
factors where diet was provided, physical activity and
sleep were monitored using actigraphy watches, there is
always a risk of poor compliance. While our actigraphy
data showed very good compliance to the sleep restriction
protocol, it was not possible to assess sleep architecture.
Using polysomnography (PSG), we could have gained a
more detailed insight of sleep experienced in each condi-
tion and assessed the relationship between certain aspects
of sleep architecture and insulin sensitivity. Future studies
should take these issues into account when examining the
influence of sleep restriction and insulin sensitivity.
In conclusion, two nights of 50% sleep restriction leads
to impaired glucose regulation in healthy males, indicated
by a reduction in whole-body insulin sensitivity. Findings
on PKB activity within skeletal muscle are unclear and
therefore would benefit from additional investigation,
including larger sample sizes. Future research should aim
to further investigate the mechanisms underlying the
impairment in glucose regulation following sleep loss.
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